(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl) 5-fluoro-1-methylindole-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl) 5-fluoro-1-methylindole-3-carboxylate
• 化学式: C₁₉H₂₃FN₂O₂
• 分子量: 330.4
• InChiKey: WIENKRUYRJECFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  34.5
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• 5HT-3 antagonists for prevention of dependence
  申请人：SANDOZ AG

  公开号：EP0302008A2

  公开（公告）日：1989-02-01

  The invention provides use of a 5HT-3 antagonist in the manufacture of a medicament suitable for the prevention or reduction of dependence on a dependence-inducing agent.

  本发明提供了 5HT-3 拮抗剂在制造适用于预防或减少对依赖性诱导剂依赖的药物中的用途。
• Treatment of movement disorders by administration of 5-hydroxytryptamine receptor/alpha2 adrenergic receptor antagonist compositions
  申请人：——

  公开号：US20020035057A1

  公开（公告）日：2002-03-21

  A method of combating movement disorder in a patient experiencing or susceptible to same, by administering to the patient an effective amount of a neurotransmission modulating composition including a 5HT antagonist and/or &agr; 2 antagonist. The antagonist may for example include a piperazinoazepine compound such as mirtazapine that is a receptor antagonist for 5HT2/3 and &agr; 2 receptors.

  一种防治运动障碍患者或易患运动障碍患者运动障碍的方法，通过向患者施用有效量的神经传递调节组合物，包括 5HT 拮抗剂和/或 &agr； 2 拮抗剂。例如，拮抗剂可包括哌嗪氮杂卓化合物，如米氮平，它是 5HT2/3 和 &agr； 2 受体的拮抗剂。
• Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists
  申请人：Tedford E. Clark

  公开号：US20060035889A1

  公开（公告）日：2006-02-16

  Methods for screening specific biological endpoints that can be utilized to identify potential therapeutic agents for METH addiction. In one aspect of the invention, the methods involve reversal of behavioral sensitization and/or conditioned place preference in an animal previously treated with METH in the presence of a known amount of a 5-HT 2A/2C antagonist or a selective 5-HT 2C antagonist, and reversal of the electrophysiological endpoints in a METH-treated animal in the presence of a known amount of the 5-HT 2A/2C antagonist or the selective 5-HT 2C antagonist. Therapeutic treatment methods for reversing the set of biological endpoints that change in the METH drug addict using mirtazapine, SDZ SER 082, and related serotonin antagonists are also provided. The methods of the invention may be utilized in the identification of potential new therapies for multiple drugs of abuse.

  筛选特定生物终点的方法，可用于确定治疗 METH 上瘾的潜在药物。在本发明的一个方面，这些方法涉及在已知量的 5-HT 2A/2C 拮抗剂或选择性 5-HT 2C 拮抗剂，并在已知量的 5-HT 2A/2C 拮抗剂或选择性 5-HT 2C 拮抗剂。本发明还提供了使用米氮平、SDZ SER 082 和相关血清素拮抗剂逆转 METH 吸毒成瘾者生物终点变化的治疗方法。本发明的方法可用于鉴定多种滥用药物的潜在新疗法。
• Treatment of gastrointestinal disorders using 5-HT3 antagonists
  申请人：SANDOZ AG

  公开号：EP0189002B1

  公开（公告）日：1993-03-03
• USE OF SEROTONIN ANTAGONISTS (5HT 3) FOR TREATING FIBROMYALGIA
  申请人：Novartis AG

  公开号：EP0804196B1

  公开（公告）日：2002-10-02